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ABSTRACT
The regulation of human exposures to potential carcinogens constitutes society’s
most important use of animal carcinogenicity data. However, for environmental
contaminants of greatest U.S. concern, we found that in most cases (58.1%;
93/160) the U.S. Environmental Protection Agency (EPA) considered the animal
data inadequate to support a classification of probable human carcinogen or noncarcinogen.
The World Health Organisation’s International Agency for Research on Cancer
(IARC) is a leading international authority on carcinogenicity assessments. For
chemicals lacking human exposure data (the great majority), IARC classifications of
identical chemicals were significantly more conservative than EPA classifications
(p<0.0001), indicating that: (i) the EPA is over-reliant on animal carcinogenicity
data, (ii) as a result, it tends to over-predict carcinogenic risk, and (iii) the true
predictivity for human carcinogenicity of animal data is even poorer than indicated
by EPA figures alone. EPA policy erroneously assuming that tumours in animals are
indicative of human carcinogenicity is implicated as the greatest source of these
errors.
* Summarised from the poster Animal carcinogenicity studies: poor human predictivity by Andrew
Knight, Jarrod Bailey and Jonathan Balcombe, which received the Animal Welfare Poster Award from
Deutscher Tierschutzbund (the German Animal Welfare Federation) at the 5th World Congress on
Alternatives and Animal Use in the Life Sciences, Berlin, 25 August 2005. Reproduced with permission
from the complete paper: Knight, A., Bailey, J., Balcombe, J. (2006). Animal carcinogenicity studies:
1. poor human predictivity. Alternatives to Laboratory Animals 34(1), 19-27.

INTRODUCTION
Since the first animal carcinogenicity test in 1915, when Yamagiwa and Ichikawa
showed that coal tar applied to rabbits’ ears caused skin carcinomas, several
thousand carcinogenicity bioassays have been conducted, with the objective of
determining human carcinogenic risks for the great majority of chemicals lacking
human exposure data (Huff, 1999). However, animal carcinogenicity testing
remains a controversial area of research.
Proponents claim that all known human carcinogens that have been studied in
sufficient animal species have produced positive results in one or more species
(Wilbourn et al., 1986; Tomatis et al., 1989; Rall, 2000). Critics respond that if
enough animal testing is conducted, carcinogenesis will eventually occur in some
species, regardless of human cancer risk. A study published in Mutagenesis found
that of 20 human non-carcinogens, 19 produced carcinogenic effects in animals
(Ennever et al., 1987).
The most important use of animal carcinogenicity data lies in the regulation of
human exposures to potential carcinogens. The U.S. Federal agency most
responsible for regulating exposures to environmental contaminants is the
Environmental Protection Agency (EPA, undated a), and the chemicals of greatest
public health concern (EPA, undated b) are listed within its Integrated Risk
Information System (IRIS) chemicals database, along with their animal toxicity
data and consequent human carcinogenicity assessments (EPA, undated c).
To assess the utility of animal carcinogenicity data in deriving human
carcinogenicity assessments, we surveyed the IRIS chemicals database. To assess
the reliability of the EPA carcinogenicity assessments obtained from animal test
data, we compared them with those of a leading world authority, the World Health
Organization’s International Agency for Research on Cancer (IARC).
METHODS
The 543 chemicals catalogued in the EPA’s IRIS chemicals database (as of January
1, 2004; EPA, undated d) were examined to determine the proportion for which the
EPA was able to derive classifications of “probable human carcinogen” or “probable
human non-carcinogen” based primarily on animal carcinogenicity data. The
relatively few classifications of “definite human carcinogen” relied primarily on
available human exposure data. The remaining classifications of “unclassifiable” or
“possible human carcinogen” were not considered substantially useful for risk
assessment or regulatory purposes. They are excluded from the U.S. National
Toxicology Program annual Report on Carcinogens (NTP, 2002).

Of the 177 chemicals considered by the EPA to possess at least limited human or
animal data, 128 were assigned human carcinogenicity classifications by both the
EPA and the IARC. Of these 128, 17 were considered by the EPA to possess at least
limited human data, while 111 were primarily reliant on animal data.
The consistency of classifications between the EPA and the IARC was examined for
these two groups by comparing the carcinogenicity classification proportions within
each group by chi-square tests, 1 and also by comparing the individual
classifications of the 111 chemicals primarily reliant on animal carcinogenicity data.
Chi-squared tests provide statistical calculations of the probability that two data
sets, such as EPA and IARC human carcinogenicity classifications, are samples from
the same underlying data population, and that any observed differences are simply
due to random sampling variation. Large chi-squared (X2) values reflect increased
probabilities that observed differences are due to real differences in underlying data
populations.
RESULTS
EPA human carcinogenicity classifications
Of the 543 chemicals catalogued in the EPA’s IRIS chemicals database, 235 had
been assigned human carcinogenicity classifications. Of these, 17 were classified as
definite (A) or probable (B1) human carcinogens on the basis of their human
carcinogenicity data. Of the remaining 218 chemicals lacking even limited human
data, 160 were deemed to possess animal carcinogenicity data, primarily sourced
from the biomedical literature (B2, C, subset of D, and E; tab. 1).
The human utility of animal carcinogenicity data based on EPA figures
Of the 160 EPA chemicals lacking even limited human data (A or B1) but having
animal data (B2, C, subset of D, and E), 64 were considered probable human
carcinogens (B2), and three were considered probably not carcinogenic to humans
(E). The remaining 93 chemicals were considered possible human carcinogens (C;
40) or unclassifiable as to their human carcinogenicity (D; 53) based on animal
data considered inadequate to support a stronger classification (tab. 1).
In sum, of those 160 chemicals lacking even limited human data but having animal
data, the EPA considered the animal data inadequate to support the substantially
useful classifications of probable human carcinogen or probable human noncarcinogen in the majority of cases (93/160; 58.1%, 95% CI: 50.4-65.5)2.

Comparison of EPA and IARC human carcinogenicity classifications
Of those 177 chemicals considered by the EPA to possess human or animal data (A,
B1, B2, C, D with animal data, or E), 128 were also assessed by the IARC. Of these,
17 were considered by the EPA to possess at least limited human data (A or B1),
and the remaining 111 EPA carcinogenicity classifications were primarily reliant on
animal data.
For those 17 chemicals considered by the EPA to possess at least limited human
data, overall EPA classifications were not found to differ significantly from those
predicted by IARC classifications (p = 0.5896, X2 = 0.291, 1 df, tab. 2)3.
However, for those 111 chemicals considered by the EPA to lack even limited
human data, but to possess animal data, EPA and IARC classifications were very
significantly different overall (p < 0.0001, X2 = 215.548, 2 df; fig. 1)4.
The EPA was much likelier than the IARC to assign carcinogenicity classifications
indicative of greater human hazard. The EPA classified 60 chemicals as probable
human carcinogens and 51 in all other categories, which was very significantly
different from the IARC figures of 12 and 99, respectively (p < 0.0001, X2 =
215.273, 1 df). Similar disparities were found for possible human carcinogens (X2
= 19.771, 1 df, p < 0.0001) and unclassifiable chemicals (p < 0.0001, X2 =
24.378, 1 df).
Comparison of the individual classifications of these 111 chemicals revealed that 67
(60.4%) were assigned an EPA carcinogenicity classification indicative of greater
human hazard, 38 (34.2%) were assigned an equivalent classification, and 6
(5.4%) were assigned a classification indicative of lesser human hazard than the
corresponding IARC classification of the same chemical.
DISCUSSION
Based on EPA figures alone, the predictivity of animal carcinogenicity data for
human hazard, and hence its utility in deriving substantially useful human
carcinogenicity classifications, is clearly poor. Of those 160 IRIS chemicals lacking
even limited human data but possessing animal data, the EPA considered the
animal data inadequate to support substantially useful human carcinogenicity
classifications in the majority (58%) of cases.
However, IARC assessments of the same chemicals reveal that the human utility of
animal carcinogenicity data is probably even lower than indicated by EPA figures.
EPA and IARC carcinogenicity classifications were similar only for those
chemicalswith human data. For those with only animal data, the EPA

was much likelier than the IARC to assign carcinogenicity classifications indicative
of greater human hazard. Given that the IARC is recognised as a leading
international authority on human carcinogenicity classifications (Tomatis et al.,
1993; IARC undated), the very significant differences in classifications of identical
chemicals between the IARC and the EPA indicate that:
- (i) in the absence of significant human data the EPA is over-reliant on animal
carcinogenicity data,
- (ii) as a result, the EPA tends to over-predict carcinogenic risk, and
- (iii) the true human predictivity for human carcinogenicity of animal data is even
poorer than indicated by EPA figures alone.
EPA human carcinogenicity classifications appear to be less scientifically-based than
those of the IARC, due to: 1) the varying depth of EPA assessments, due to
resource constraints; 2) the less rigorous standards required of data incorporated
into EPA assessments; and, in particular, 3) EPA public health-protective policy,
which errs on the side of caution by assuming that tumours in animals are
indicative of human carcinogenicity (Knight et al. 2006).
Our findings corroborate those of previous investigators. In response to a 2000
Congressional directive, the EPA undertook an evaluation of the data variability and
uncertainty within its IRIS assessments. A representative sample of 16 IRIS
assessments was subjected to in-depth evaluation by a panel of six independent
experts, who concluded that despite being advertised as quantitative science-based
classifications, some were, in fact, more grounded in EPA policy favouring
classifications indicative of greater human risk (Hogan, 2000).
EPA carcinogenicity assessments may be no more suspect than those of other U.S.
regulatory agencies, however. In their survey of 350 representative chemicals,
Viscusi and Hakes (1998) found that the carcinogenicity assessments of other U.S.
regulatory authorities, particularly the Food and Drug Administration and the
Occupational Safety and Health Administration, are even less reflective of actual
human risk than those of the EPA. Poor human predictivity of animal carcinogenicity
studies was also demonstrated by Tomatis and Wilbourn (1993) and Haseman
(2000), and further described by Rall (2000), Ashby and Purchase (1993), Fung et
al. (1995) and Ennever and Lave (2003).
CONCLUSIONS
By 1998, only about 2,000 (2.7%) of the 75,000 industrial chemicals in use and
listed in the EPA’s Toxic Substances Control Act inventory had been tested for
carcinogenicity (Epstein, 1998). The cost of testing these 2.7% of industrial
chemicals was millions of animal lives (Monro et al., 1998; Gold et al., 1999),

millions of skilled personnel hours (Gold et al., 1999), and hundreds of millions of
dollars (Greek et al., 2000; Stephens et al., 1998).
The most important use of the animal data thus derived is in the regulation of
human exposures to potential carcinogens by governmental agencies such as the
EPA. However, our results demonstrate that the human predictivity of animal
carcinogenicity data was inadequate for the EPA to derive substantially useful
human carcinogenicity classifications for the majority (58.1%) of chemicals of
greatest public health concern.
Profound differences in human carcinogenicity classifications of identical chemicals
between the EPA and the IARC reveal an over-reliance on animal carcinogenicity
data by the EPA. The result is that the EPA over-predicts carcinogenic risk. Hence
the true human predictivity of animal carcinogenicity data is even poorer than
indicated by EPA figures alone.
The sensitivity of the traditional rodent bioassay in detecting human carcinogens for
some sex-species combinations is not in question. However, its very poor human
specificity severely limits its utility for identifying human carcinogens, and its
subsequent use in regulating exposures to them. The implementation by regulatory
authorities of alternative assays with superior human predictivity is clearly
necessary.

Table 1. EPA human carcinogenicity classifications of IRIS chemicals

EPA human carcinogenicity classification (with basis for classification)

A: Human carcinogen (convincing human data)
B1: Probable human carcinogen (limited human data)
B2: Probable human carcinogen (sufficient animal data)
C: Possible human carcinogen (animal data inadequate for stronger
classification)
D: Unclassifiable (animal data inadequate for stronger classification)
D: Unclassifiable (no animal or human data)
E: Probable human non-carcinogen (sufficient animal data)
TOTAL

# of
chemicals

% of
Total

11
6
64

4.7
2.6
27.2

40

17.0

53
58
3
235

22.6
24.7
1.3

160 chemicals lacking in human data had received a human carcinogenicity assessment primarily on
the basis of their animal data.
Data source: EPA Integrated Risk Information System database, 1 January 2004.

Table 2. IARC classifications of EPA chemicals possessing significant human data (EPA
categories A or B1)
Human carcinogenicity classification

EPA

IARC

Human Carcinogen (A)
Probable Human Carcinogen (B1)
Possible Human Carcinogen
Total

11
6
0
17

12
4
1
17

Data sources: The EPA Integrated Risk Information System database, 1 January 2004, and the IARC
Monographs Programme on the Evaluation of Carcinogenic Risks to Humans, Volumes 1-82, 1 January
2004.

Figure 1. EPA and IARC human carcinogenicity classifications of chemicals considered by
the EPA to lack human data but to possess animal data.

Data source: IARC Monographs Programme on the Evaluation of Carcinogenic Risks to Humans, and
the EPA Integrated Risk Information System database, Jan. 1, 2004.

1
Chi-squared and two-tailed p values were derived from the online statistical calculators available at
www.graphpad.com/quickcalcs/index.cfm.
2
Confidence interval derived via the modified Wald method described by Agresti et al. (1998) as being more
accurate than the so-called “exact” method commonly used.
3
Chi-squared analysis does not allow comparison when one category lacks any data, hence acrylonitrile, assessed
as the only possible human carcinogen by IARC, but as a probable human carcinogen (B1) by the EPA, was
excluded, yielding a more conservative result.
4
To allow chi-squared analysis, methacrylate, assessed as unclassifiable by IARC, but as the only probable human
non-carcinogen by the EPA, was excluded, yielding a more conservative result.
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